Consistent with the latter idea, Kay et al. (45) reported that loss of Nrf2 greatly exacerbates stimulation of NASH by the LXRα agonist T0901317, whereas activation of Nrf2 by administration of sulforaphane inhibited NASH caused by the LXRα agonist. Here, NFE2L2 is linked to metabolic dysfunction-associated steatohepatitis.